Dermasensor, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2024 | $9 M | No. 4 | $2 to $10 million | equity | SEC | |
| Dec 2021 | $9 M | No. 3 | $2 to $10 million | equity | SEC | |
| Feb 2020 | $6 M | No. 2 | $2 to $10 million | equity | SEC | |
| Nov 2018 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Dermasensor, Inc. reported revenue of $418,596 for its most recent fiscal year (filed Sep 2026), up from $107,717 the year before.
SEC Form C/A · Sep 2026
The direct cost of what it sold was $99,407, so 76% of its revenue was left after those costs.
SEC Form C/A · Sep 2026
Net loss for the same year: $6.70 million.
SEC Form C/A · Sep 2026
Dermasensor, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2024).
SEC Form D · Dec 2024
The industry group it chose in its notices: Other.
SEC Form D · Dec 2024
In its own words
How the company describes itself to search engines on its website, word for word.
“An AI-powered device helping physicians detect skin cancer at the point of care, with 96% sensitivity across all three common skin cancers. Request a demo.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of Dermasensor, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 168 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Cody Simmons | Executive officer | Dec 2024 |
| Cristiane Benvenuto | Chief Medical Officer | Mar 2020 |
| Christopher Dewey | Director | Dec 2024 |
| Cody Simmons | Director | Dec 2024 |
| David Matlin | Director | Dec 2024 |
| Maurice Ferre | Director | Dec 2024 |
| Ivan Delevic | Director | Mar 2020 |